Overview
Levodopa-unresponsive juvenile parkinsonism is a term that was previously used to describe a form of parkinsonism that begins in childhood or adolescence and does not improve with levodopa treatment. Parkinsonism refers to a group of movement problems that include tremor (shaking), stiffness in the muscles, slowness of movement, and difficulty with balance and walking. In most forms of Parkinson disease, the medication levodopa helps relieve symptoms, but in this particular form, patients do not experience meaningful improvement with levodopa therapy. This distinction is important because it suggests a different underlying cause compared to typical Parkinson disease. This entry is now considered obsolete in the Orphanet classification system, meaning it has been retired or reclassified. Patients who were previously diagnosed under this label may now fall under more specific genetic or clinical diagnoses, such as certain forms of neurodegeneration with brain iron accumulation, juvenile-onset dystonia-parkinsonism, or other rare genetic parkinsonian syndromes. If you or a family member received this diagnosis, it is strongly recommended to seek updated genetic testing and evaluation by a movement disorder specialist, as advances in genetic testing have allowed for more precise diagnoses. A more specific diagnosis can open the door to better-targeted treatments, clinical trials, and support resources. The treatment landscape for levodopa-unresponsive parkinsonism is challenging. Since levodopa does not help, doctors focus on other medications and supportive therapies such as physical therapy, occupational therapy, and speech therapy to manage symptoms and maintain quality of life.
Also known as:
Key symptoms:
Muscle stiffness or rigiditySlowness of movementTremor or shakingDifficulty walking or unsteady gaitBalance problems and frequent fallsDifficulty with fine motor tasks like writingMuscle cramping or abnormal postures (dystonia)Speech difficultiesSwallowing problemsReduced facial expressionFatigue and low energySleep disturbancesMood changes such as depression or anxiety
Variable
Can be inherited in different ways depending on the underlying gene
Juvenile
Begins in the teen years
FDA & Trial Timeline
1 eventData sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.
Start the conversation →Latest news about OBSOLETE: Levodopa-unresponsive juvenile parkinsonism
No recent news articles for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Has genetic testing been done to identify the specific cause of my parkinsonism, and should it be updated with newer tests?,Since levodopa doesn't work, what other medications or treatments might help my symptoms?,Am I a candidate for deep brain stimulation or any other surgical treatments?,Are there any clinical trials I might be eligible for?,How quickly is this condition likely to progress in my case?,What therapies (physical, occupational, speech) should I be receiving regularly?,Should my family members be tested for the same genetic condition?
Common questions about OBSOLETE: Levodopa-unresponsive juvenile parkinsonism
What is OBSOLETE: Levodopa-unresponsive juvenile parkinsonism?
Levodopa-unresponsive juvenile parkinsonism is a term that was previously used to describe a form of parkinsonism that begins in childhood or adolescence and does not improve with levodopa treatment. Parkinsonism refers to a group of movement problems that include tremor (shaking), stiffness in the muscles, slowness of movement, and difficulty with balance and walking. In most forms of Parkinson disease, the medication levodopa helps relieve symptoms, but in this particular form, patients do not experience meaningful improvement with levodopa therapy. This distinction is important because it s
At what age does OBSOLETE: Levodopa-unresponsive juvenile parkinsonism typically begin?
Typical onset of OBSOLETE: Levodopa-unresponsive juvenile parkinsonism is juvenile. Age of onset can vary across affected individuals.